Novel insights into mesothelioma biology and implications for therapy
Malignant mesothelioma is a universally lethal cancer that is increasing in incidence
worldwide. There is a dearth of effective therapies, with only one treatment (pemetrexed and …
worldwide. There is a dearth of effective therapies, with only one treatment (pemetrexed and …
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
M Wu, Q Huang, Y Xie, X Wu, H Ma, Y Zhang… - Journal of hematology & …, 2022 - Springer
Immune checkpoint molecules are promising anticancer targets, among which therapeutic
antibodies targeting the PD-1/PD-L1 pathway have been widely applied to cancer treatment …
antibodies targeting the PD-1/PD-L1 pathway have been widely applied to cancer treatment …
NCCN guidelines insights: malignant pleural mesothelioma, version 3.2016
These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines for
Malignant Pleural Mesothelioma (MPM). These NCCN Guidelines Insights discuss systemic …
Malignant Pleural Mesothelioma (MPM). These NCCN Guidelines Insights discuss systemic …
Emerging treatments for malignant pleural mesothelioma: where are we heading?
Malignant pleural mesothelioma (MPM) is an uncommon but aggressive and treatment
resistant neoplasm with low survival rates. In the last years we assisted to an exponential …
resistant neoplasm with low survival rates. In the last years we assisted to an exponential …
Prognostic and predictive aspects of the tumor immune microenvironment and immune checkpoints in malignant pleural mesothelioma
Malignant pleural mesothelioma (MPM) is an aggressive cancer with a poor prognosis and
an increasing incidence, for which novel therapeutic strategies are urgently required. Since …
an increasing incidence, for which novel therapeutic strategies are urgently required. Since …
Emerging avenues in immunotherapy for the management of malignant pleural mesothelioma
SG Gray - BMC Pulmonary Medicine, 2021 - Springer
Background The role of immunotherapy in cancer is now well-established, and therapeutic
options such as checkpoint inhibitors are increasingly being approved in many cancers such …
options such as checkpoint inhibitors are increasingly being approved in many cancers such …
[HTML][HTML] Molecular and histopathological characterization of the tumor immune microenvironment in advanced stage of malignant pleural mesothelioma
Introduction Malignant pleural mesothelioma (MPM) is a rare, highly aggressive, and
relatively chemoresistant and radioresistant malignancy with limited therapeutic options. Our …
relatively chemoresistant and radioresistant malignancy with limited therapeutic options. Our …
[HTML][HTML] Potential diagnostic and prognostic role of microenvironment in malignant pleural mesothelioma
IC Salaroglio, J Kopecka, F Napoli, M Pradotto… - Journal of Thoracic …, 2019 - Elsevier
Introduction A comprehensive analysis of the immune cell infiltrate collected from pleural
fluid and from biopsy specimens of malignant pleural mesothelioma (MPM) may contribute …
fluid and from biopsy specimens of malignant pleural mesothelioma (MPM) may contribute …
Integrated analysis of somatic mutations and immune microenvironment in malignant pleural mesothelioma
K Kiyotani, JH Park, H Inoue, A Husain… - …, 2017 - Taylor & Francis
To investigate the link between the genomic landscape of cancer cells and immune
microenvironment in tumor tissues, we characterized somatic mutations and tumor …
microenvironment in tumor tissues, we characterized somatic mutations and tumor …
[HTML][HTML] Abundant expression of TIM-3, LAG-3, PD-1 and PD-L1 as immunotherapy checkpoint targets in effusions of mesothelioma patients
Malignant pleural mesothelioma (MPM) is an aggressive cancer with an increasing
incidence, poor prognosis and limited effective treatment options. Hence, new treatment …
incidence, poor prognosis and limited effective treatment options. Hence, new treatment …